Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)

Summary / Zusammenfassung
Progress accumulated in the understanding of the genetic and immune pathogenesis of IBD, as well as the advent of modern immuno-modulating and biological therapies, have induced profound changes in the management – and possibly in the outcome - of IBD patients. However, there are major gaps in the knowledge needed for clinical decision making, including long-term drug safety of biological therapies, their interactions with older therapies, the relative benefits of the various possible treatment strategies, the chemo-prevention of colon cancer as well as the influence of current treatment options on patient physical, mental and psychosocial long-term state of health. Likewise, information available for global aspects of health care management of these patients is mostly derived from patient populations exposed to treatment strategies that are no longer the standard of care, and the impact of the novel treatment approaches is not established.

Based on the development of a population-based cohort in the State of Vaud (cohorte vaudoise), on pre-established criteria for appropriateness of care (EPACT), and taking advantage on the existence of a na-tional network of IBD-oriented laboratories, clinical centres, private practice specialists and social and psychosocial medicine as well as paediatric divisions in the country, the development of a prospective, countrywide cohort is proposed. The clinical and socio-economical data as well as the biological samples to be collected in this cohort aim in particular to analyse appropriateness of care, relations between therapy and patient out-come, impact of disease and therapy on mental health and other psychosocial factors, and economical aspects of patient care. As IBD is a typical model of chronic relapsing inflammatory condition, at least some of the information obtained through this cohort may apply to other conditions like chronic rheuma-tologic diseases or dermatological conditions. At this stage 1102 patients are included, 1065 enrolment data sets are completed, and 308 patients already underwent a first annual follow-up.

While some aspects of this project are country-specific, SIBDC is oriented towards international collabo-rations. SIBDC is one of the cohorts included in the EU framework 7 funded IBDase consortium (collabo-ration letter by Dr D. Lottaz previously submitted). SIBDC is one integral part of another project funded by the Crohn’s and Colitis Foundation of America on osteoporosis in young patients (collaboration letter by Pr. S. Ferrari previously submitted). Recently, the European Crohn’s and Colitis Organisation (ECCO) adopted the IBDIS system developed by Pr. W. Reinisch in Vienna as a recommended common data col-lection system within its member scientific communities. We have established contacts with the IBDIS to create a platform able to translate our data in this system. Early feasibility analysis showed a 75% direct homology between the data collection systems, while a further 10-15% of the SIBDC data can be modified to fit the IBNIS database system.

Within the project there is a special paediatric cohort that has been setup by the Division of Gastroenterology and Nutrition of the University Children's Hospital Zurich

Members of the SIBDC steering committee are:
Christoph Beglinger, Prof. Dr. med., Head of the center in Basel, Unispital, Basel
Christian Braegger, Prof. Dr. med., Head of the pediatric cohort, Kinderspital, Zürich
Philippe De Saussure, Dr.med., Head of local center, Geneva
Florian Froehlich, Prof. Dr. med., Head of appropriateness of care project, Priv. pract., Porrentruy and Unispital Basel
Roland von Känel, Prof. Dr. med., Head of Psychosocial Health project, Inselspital, Bern
Christa Meyenberger, Prof. Dr. med., Head of local center (St Gallen)
Pierre Michetti, Prof. Dr. med., PI for the first funding period, Head of the center in Lausanne, now in private practice, Lausanne
Christian Mottet, PD Dr. med., Head of scientific committee, Neuchatel
Christoph Mueller, Prof. Dr. phil.nat., Head of Biobank, Inselspital, Bern
Valérie Pittet, Dr.sc.tech., National cohort coordinator, Lausanne
Gerhard Rogler, Prof. Dr. med. Dr. phil., Head of the center in Zürich, University Hospital Zürich
Markus Sagmeister, PD Dr. med., Head of Socio-economic project, St Gallen
Frank Seibold, Prof. Dr. med., Head of the center in Bern, Inselspital
Alex Straumann, Prof. Dr. med., Representative of GI practitioners, Olten
John-Paul Vader, Prof. Dr.med., Head of Databank, CHUV, Lausanne
Bruno Raffa, Representative of the Crohn & Colitis patient association

Publications / Publikationen
Cámara RJ, Begré S, von Känel R. The Effect of Stress-Relieving Interventions on Inflammatory Bowel Disease: Quality Assessment of 10 Therapeutic Studies. Zeitschrift für Psychosomatische


Keywords / Suchbegriffe
Inflammatory bowel disease; Morbus Crohn; Colitis Ulcerosa; Indeterminate Colitis; Cohort, Epidemiology; Population-based study; Multicentric, Appropriateness of care, Cost-effectiveness, Mental health, Psychological stress, Quality of life, Biobank

Project Leadership and Contacts / Projektleitung und Kontakte
Prof Christian Braegger, MD (Project Leader) christian.braegger@kispi.uzh.ch
Dr Patrick Bühr, MD  patrick.buehr@kispi.uzh.ch

Funding Source(s) / Unterstützt durch
Funded by the SNF (Personen- und Projektförderung) since 2006, Beitragsnummer 3347C0-108792

In Collaboration with / In Zusammenarbeit mit
Prof. Gerhard Rogler (Principal Investigator and Study Coordinator)  Switzerland
Klinik für Gastroenterologie und Hepatologie
UniversitätsSpital Zürich

Duration of Project / Projektdauer
Jan 2009 to Mar 2017